NerPharMa
- Company typePrivate
- Founded2010
- HeadquartersNerviano, Italy
- Headcount51–100
- GTM typeB2B
- OfferingServices
NerPharMa firmographics
Firmographics- Name
- NerPharMa
- Legal name
- Nerpharma S.r.l
- Website
- https://nerpharma.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
NerPharMa industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing Services (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMOHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)Small-Molecule API & Intermediates CDMOHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)Clinical Trial Material (CTM) Manufacturing & Supply CDMOHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing ServicesGMP Scale-Up, Tech Transfer & Process Validation (PPQ)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Keywords
Where NerPharMa is headquartered
LocationHeadquarters
- HQ city
- Nerviano
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
NerPharMa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: NerPharMa generates revenue through providing GMP-compliant contract manufacturing services for pharmaceutical active ingredients (API/drug substance) and finished pharmaceutical products (drug product). Services include development and scale-up, regulatory support, clinical supply, and analytical services. The company operates as a CDMO with both DS and DP divisions serving global pharmaceutical clients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Contract-based manufacturing services for pharmaceutical companies |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NerPharMa product offering
Product offeringCore offering
NerPharMa is a Contract Development and Manufacturing Organization (CDMO) specializing in oncology, operating two divisions—NerPharMa DS (Drug Substance) for high-potency active pharmaceutical ingredient (API) manufacturing including Protein Kinase Inhibitors and cytotoxic/cytostatic compounds, and NerPharMa DP (Drug Product) for injectable products (solutions, suspensions, lyophilized) and oral solid products (tablets, capsules). The company provides integrated services including API development and scale-up, contract manufacturing, clinical supply, regulatory support, and analytical services for global pharmaceutical and biotechnology clients.
Product overview
NerPharMa operates as a Contract Development and Manufacturing Organization (CDMO) specializing in oncology, with two core divisions: NerPharMa DS (Drug Substance) and NerPharMa DP (Drug Product). NerPharMa DS develops and manufactures active pharmaceutical ingredients exclusively for oncology (Protein Kinase Inhibitors, cytotoxic/cytostatic compounds) from laboratory to commercial scale. NerPharMa DP supports development and production of injectable products (solutions, suspensions, lyophilized products) and oral solid products (tablets, capsules). The company offers integrated services including development and scale-up, contract manufacturing, regulatory services, clinical supply, and analytical services. The company has over 15 products on the market, with unique innovative technologies including dual chamber bags and HyNap nanoparticle technology.
Differentiator
Problem solved
Functional benefit
Products and services
- NerPharMa DS (Drug Substance) Manufacturing Development and manufacturing of active pharmaceutical ingredients (APIs) exclusively for oncology applications including Protein Kinase Inhibitors, cytotoxic and cytostatic compounds, from laboratory scale to commercial production under cGMP with multi-regulatory approval (FDA, EMA, AIFA, ANVISA Brazil, China FDA, PMDA Japan, Russia).
- NerPharMa DP (Drug Product) Manufacturing Contract development and production of injectable products (solutions, suspensions, and lyophilized products) and oral solid products (tablets and capsules) for various therapeutic areas, handling Protein Kinase Inhibitors, cytotoxic and cytostatic products, with formulation, packaging, and distribution activities. Authorized by AIFA for medicinal product manufacture and packaging.
- Development and Scale-up Services Full support from API synthetic route development through formulation, process development, analytical methods, scale-up, technology transfer, regulatory filing support, and commercial manufacturing for pharmaceutical clients.
- Regulatory Services Guidance and consulting in IMPD, IND, DMF, CMC and dossier preparation and filing, with CMC section support for IND, NDA, and ANDA filings across the EU, US, and Japan for pharmaceutical clients.
- Clinical Supply Services Manufacturing, labeling, packaging, and distribution of investigational medicinal products from laboratory to production scale for Phase 1 through Phase 4 clinical studies, including patient kit assembly combining primary and associated drug products.
- Analytical Services Comprehensive analytical testing including method development and validation, ICH stability studies, dissolution profiles, impurity characterization, and full solid state analysis to certify and release pharmaceutical products.
Quantifiable outcome
- More than 15 products successfully commercialized
- +2 more outcomes
Companies that use NerPharMa
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
NerPharMa technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NerPharMa partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BrYet Health InccoreManufacturing Development Agreement for BrYet's lead product candidate ML-016 against lung and liver metastases from breast cancer. NerPharMa to scale-up drug substance manufacturing process and finished product to supply material for clinical programs with potential for future world-wide commercial sales.
- ICROM srlcorePartnership Agreement with ICROM srl for collaboration on commercial production of High Potent drugs and ADC-Payload. The agreement outlines sharing of technologies, know-how, facilities and workforce to offer API development and formulated drug production services to third-party companies in strategic sectors of oncology and neurology.
- Xspray PharmacoreThird-party manufacturing partner for Xspray's Dasynoc (leukemia drug). NerPharMa serves as the manufacturing site where FDA identified unresolved manufacturing concerns leading to Complete Response Letter. Xspray plans to resubmit with additional commercial-scale batch data.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
NerPharMa competitors and assessment
Company assessmentDirect peers
- BSP Pharmaceuticals: Italian CDMO focused on high-potency oncology manufacturing, including HP-APIs, antibody-drug conjugates, and sterile injectable manufacturing. Comparable in scale, geography, and oncology specialization to NerPharMa.
- Olon S.p.A. Italian-headquartered global API CDMO with strong generic and oncology API manufacturing capabilities, including high-potency compounds. Directly comparable as an Italian small-molecule CDMO serving pharma clients.
- Corden Pharma: European CDMO offering HP-API, injectable, and oral solid dose manufacturing, including high-potency containment. Comparable in technical capabilities and customer base to NerPharMa.
- Piramal Pharma Solutions: Global CDMO with significant high-potency API and sterile injectable manufacturing capabilities, including oncology assets. Comparable in scale and oncology-focused service offering to NerPharMa.
- Axplora: European CDMO (formerly Farmabios, acquired by Avista Capital) specializing in HP-API and complex small-molecule manufacturing, including oncology. Comparable in technical scope and target customer base to NerPharMa.
Broad incumbents
- Catalent: Large global CDMO (now owned by Novo Holdings) offering broad HP-API, sterile injectable, and oral solid dose capabilities across multiple therapeutic areas. Overlaps with NerPharMa in oncology and HP manufacturing but serves a much wider portfolio.
- Lonza: World's largest CDMO with extensive HP-API, biologics, and small-molecule manufacturing capabilities. Competes with NerPharMa in oncology API and drug product but at vastly greater scale and geographic reach.
- EuroAPI: European API manufacturer (Sanofi spinoff) producing small-molecule APIs across multiple therapeutic areas, including complex chemistry. Comparable in CDMO API services but with broader scope and public-company scale.
Regional players
- Aenova: European-headquartered CDMO focused on solid oral dosage forms, sterile liquids, and HP compounds. Comparable to NerPharMa's drug product services and shares a European pharma client base.
- FAREVA: French-headquartered CDMO with API, sterile injectable, and topical manufacturing capabilities across Europe. Comparable as a European mid-sized CDMO serving pharma customers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NerPharMa social profiles
Digital presenceNerPharMa compliance and trust
Trust signalCompliance8 records
NerPharMa financial estimates
Financial estimateRevenue estimate
Valuation estimate
NerPharMa leadership team
Management profileNumber of profiles
Profiles6 records
NerPharMa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NerPharMa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NerPharMa
What does NerPharMa do?
NerPharMa is a Contract Development and Manufacturing Organization (CDMO) specializing in oncology, operating two divisions—NerPharMa DS (Drug Substance) for high-potency active pharmaceutical ingredient (API) manufacturing including Protein Kinase Inhibitors and cytotoxic/cytostatic compounds, and NerPharMa DP (Drug Product) for injectable products (solutions, suspensions, lyophilized) and oral solid products (tablets, capsules). The company provides integrated services including API development and scale-up, contract manufacturing, clinical supply, regulatory support, and analytical services for global pharmaceutical and biotechnology clients.
Is NerPharMa a public or private company?
NerPharMa is a private company. It is classified as corporate owned and is currently operating.
When was NerPharMa founded?
NerPharMa was founded in 2010. It employs 51 to 100 people.
Where is NerPharMa based?
NerPharMa is headquartered in Nerviano, Italy, in the Europe region.
How does NerPharMa make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are NerPharMa's main competitors?
Direct peers on record are BSP Pharmaceuticals, Olon S.p.A., Corden Pharma, Piramal Pharma Solutions and Axplora. Broad incumbents are Catalent, Lonza and EuroAPI. Regional players are Aenova and FAREVA.
Does NerPharMa have an API?
No public API is recorded for NerPharMa.
What industry is NerPharMa in?
NerPharMa's product category is Pharmaceutical Contract Manufacturing Services (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 32541 and its SIC code is 2834.